Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wendys Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Wendys Co trades at $7.52 (market cap $1.44B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 27.7× Wendys Co's market cap, and Wendys Co pays a 7.41% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WEN | |
|---|---|---|
Market Cap | $39.89B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $11.33 |
52-Week Low | $278.09 | $6.17 |
Enterprise Value | $38.15B | $5.26B |
Dividend Yield | — | 7.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Wendy's (WEN) trades at $7.55, down 0.53% on the day, amid mixed technical signals with a bullish overall trend but neutral oscillators. The stock shows attractive valuation metrics with a P/E of 9.82 and P/S of 0.66, though net income margins have declined from 9.37% in 2023 to 6.77% in 2026. Recent earnings beats and a 7.1% dividend yield provide support, while meme stock volatility and competitive pressures create uncertainty.
The outlook balances value appeal against growth challenges. Positive factors include consistent earnings beats, strong ROE of 120.88%, and analyst consensus price target of $7.96 offering 5.4% upside. Risks include declining profitability, high debt levels (debt-to-asset ratio of 55.68%), and reliance on meme-driven momentum rather than fundamental improvement for recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
